Abstract:Antidepressant drugs such as the serotonin (5-HT)/norepinephrine (NE) and dopamine (DA) reuptake inhibitors activate monoaminergic neurotransmission in various brain regions, such as the amygdala, the frontal cortex or the hippocampus. Although this property is well established, the post-synaptic mechanisms by which these pharmacological agents exert therapeutic activity in major depressive disorders (MDD) is not fully understood. Recent clinical and preclinical studies have indicated that the density and reactivity of glia and more particularly of astrocytes are reduced in MDD patients. These data along with the fact that astrocytes express monoaminergic transporters and receptors make these cells putative targets for antidepressant treatments. Accordingly, in vitro evidence has demonstrated that the application of various classes of antidepressant drugs on rodent primary astrocyte cultures elicits a wide spectrum of responses, from the rise in cytosolic calcium concentrations, as a marker of cellular activity, to the release of glucose metabolites, gliotransmitters and neurotrophic factors. Remarkably, antidepressant drugs also attenuate the release of inflammatory molecules from reactive astrocytes or microglia, suggesting that part of the beneficial effects in depressed patients or animal models of depression might result from the ability of antidepressants to regulate the synthesis and release of psychoactive substances acting on both pre- and post-synaptic neurons. Among the many long-term targets of antidepressant drugs, brainderived neurotrophic factor (BDNF) has been well studied because of the positive influence on adult hippocampal neurogenesis, synaptogenesis and the local serotonergic tone. This review will illustrate how the concept of the tripartite synapse, which is classically associated with different forms of plasticity involving glutamate, could be expanded to the monoaminergic systems to regulate antidepressant drug responses. The recent in vivo data supporting that hippocampal astrocytes act in concert with neurons to release BDNF under pharmacological conditions and thereby regulate different facets of anxiolytic-/antidepressant-like activities through neurogenesis-dependent and independent mechanisms will be emphasized.

Research Progress in Monoamine Transporters and Monoamine Transmitter Reuptake Inhibitors

[Progress of Monoaminergic Receptor Investigation on Depression].

Structure-Based Specific Detection And Inhibition Of Monoamine Oxidases And Their Applications In Central Nervous System Diseases

Monoamine transporters: vulnerable and vital doorkeepers.

Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters.

Serotonin transporter progress

Interaction of antidepressants with the serotonin and norepinephrine transporters: mutational studies of the S1 substrate binding pocket

Advances in Novel MolecularTargets for Antidepressants

Triple reuptake inhibitors: a patent review (2006 - 2012).

Regulation of monoamine transporters: Role of transporter phosphorylation

Molecular basis of human noradrenaline transporter reuptake and inhibition

Recent Developments in the Design of Anti-Depressive Therapies: Targeting the Serotonin Transporter

Involvement of Organic Cation Transporter 2 Inhibition in Potential Mechanisms of Antidepressant Action

Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins

The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs

Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors

Research Progress of Relationship Between Serotonin Transporter Gene Promoter Region Polymorphism and Depression

Dimerization and antidepressant recognition at noradrenaline transporter

Multifaceted Regulations of the Serotonin Transporter: Impact on Antidepressant Response

The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants

Comparison of computational model and X-ray crystal structure of human serotonin transporter: potential application for the pharmacology of human monoamine transporters